JP2001526220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001526220A5 JP2001526220A5 JP2000525097A JP2000525097A JP2001526220A5 JP 2001526220 A5 JP2001526220 A5 JP 2001526220A5 JP 2000525097 A JP2000525097 A JP 2000525097A JP 2000525097 A JP2000525097 A JP 2000525097A JP 2001526220 A5 JP2001526220 A5 JP 2001526220A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- urea
- butyl
- group
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 description 182
- 125000003118 aryl group Chemical group 0.000 description 121
- 229910052736 halogen Inorganic materials 0.000 description 105
- 150000002367 halogens Chemical class 0.000 description 105
- -1 1-methyl-3-tert-butyl-5-pyrazolyl Chemical group 0.000 description 56
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 55
- 239000004202 carbamide Substances 0.000 description 55
- 150000001875 compounds Chemical class 0.000 description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 46
- 125000000753 cycloalkyl group Chemical group 0.000 description 38
- 125000004076 pyridyl group Chemical group 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 125000002877 alkyl aryl group Chemical group 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 229910052717 sulfur Chemical group 0.000 description 20
- 150000002431 hydrogen Chemical class 0.000 description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 18
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 16
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Chemical group 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000011593 sulfur Chemical group 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- MQQZEXCPOASVFI-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 MQQZEXCPOASVFI-UHFFFAOYSA-N 0.000 description 4
- UDYOWLBACWDBNL-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 UDYOWLBACWDBNL-UHFFFAOYSA-N 0.000 description 4
- NISMKTLRQBAMPS-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound N1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=N1 NISMKTLRQBAMPS-UHFFFAOYSA-N 0.000 description 4
- NIQFSOWYCXNLNI-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 NIQFSOWYCXNLNI-UHFFFAOYSA-N 0.000 description 4
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 4
- FDHKHZIFBOZGKU-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 FDHKHZIFBOZGKU-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- MTTAQONWKYZSGQ-UHFFFAOYSA-N 1-(3-benzoylphenyl)-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(C=CC=2)C(=O)C=2C=CC=CC=2)=N1 MTTAQONWKYZSGQ-UHFFFAOYSA-N 0.000 description 2
- NNGZTFCLDJGBAR-UHFFFAOYSA-N 1-(3-propan-2-yl-1,2-oxazol-5-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 NNGZTFCLDJGBAR-UHFFFAOYSA-N 0.000 description 2
- ZLRZULLSROJBLS-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 ZLRZULLSROJBLS-UHFFFAOYSA-N 0.000 description 2
- ORIFMUAUSBIDGC-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 ORIFMUAUSBIDGC-UHFFFAOYSA-N 0.000 description 2
- YSOLQZIGFKVUPX-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 YSOLQZIGFKVUPX-UHFFFAOYSA-N 0.000 description 2
- QNPSZGWMKYQMSH-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NO1 QNPSZGWMKYQMSH-UHFFFAOYSA-N 0.000 description 2
- KDXIBGWSUXXMBV-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(4-methylpyridin-3-yl)oxyphenyl]urea Chemical compound CC1=CC=NC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NO1 KDXIBGWSUXXMBV-UHFFFAOYSA-N 0.000 description 2
- KXEOEENRCKNIJO-UHFFFAOYSA-N 1-(3-tert-butyl-1,2-oxazol-5-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 KXEOEENRCKNIJO-UHFFFAOYSA-N 0.000 description 2
- RBTTWKACKBLWGC-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(OC=3C=CN=CC=3)C=CC=2)=N1 RBTTWKACKBLWGC-UHFFFAOYSA-N 0.000 description 2
- BWYIEKUXLAWWDO-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(SC=3C=CN=CC=3)C=CC=2)=N1 BWYIEKUXLAWWDO-UHFFFAOYSA-N 0.000 description 2
- ANWRKPQVLGBTCG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 ANWRKPQVLGBTCG-UHFFFAOYSA-N 0.000 description 2
- XIGJMGPUXKZADA-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-3-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=NC=CC=3)=CC=2)=N1 XIGJMGPUXKZADA-UHFFFAOYSA-N 0.000 description 2
- XKNAGLMNQADBQE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CN=CC=3)=CC=2)=N1 XKNAGLMNQADBQE-UHFFFAOYSA-N 0.000 description 2
- MBPSLEWGDKMGQY-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=N1 MBPSLEWGDKMGQY-UHFFFAOYSA-N 0.000 description 2
- OCVLLNOZMGLZMR-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(3-methylpyridin-4-yl)oxyphenyl]urea Chemical compound CC1=CN=CC=C1OC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 OCVLLNOZMGLZMR-UHFFFAOYSA-N 0.000 description 2
- RVAHNWTXRHZRLG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(3-methylpyridin-4-yl)sulfanylphenyl]urea Chemical compound CC1=CN=CC=C1SC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 RVAHNWTXRHZRLG-UHFFFAOYSA-N 0.000 description 2
- RQOXVIHEZQVYGS-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-(4-methylpyridin-3-yl)oxyphenyl]urea Chemical compound CC1=CC=NC=C1OC1=CC=CC(NC(=O)NC2=NOC(=C2)C(C)(C)C)=C1 RQOXVIHEZQVYGS-UHFFFAOYSA-N 0.000 description 2
- ZNHFSYPNHIOTRT-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-hydroxyphenoxy)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=C(O)C=CC=3)=CC=2)=N1 ZNHFSYPNHIOTRT-UHFFFAOYSA-N 0.000 description 2
- VJWFZMSZAJHSFF-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-methylpyridin-4-yl)oxyphenyl]urea Chemical compound CC1=CN=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 VJWFZMSZAJHSFF-UHFFFAOYSA-N 0.000 description 2
- WFBGXNIMCQEGOX-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-methylpyridin-4-yl)sulfanylphenyl]urea Chemical compound CC1=CN=CC=C1SC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 WFBGXNIMCQEGOX-UHFFFAOYSA-N 0.000 description 2
- DMQFIGFOGVTSFP-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(4-hydroxyphenoxy)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC(O)=CC=3)=CC=2)=N1 DMQFIGFOGVTSFP-UHFFFAOYSA-N 0.000 description 2
- CJUNRHGYKDHACB-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(CC=3C=CN=CC=3)=CC=2)=N1 CJUNRHGYKDHACB-UHFFFAOYSA-N 0.000 description 2
- PXMZWZHOSUYALM-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2C=CN=CC=2)=C1 PXMZWZHOSUYALM-UHFFFAOYSA-N 0.000 description 2
- MSMDSZZGUDIFPB-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 MSMDSZZGUDIFPB-UHFFFAOYSA-N 0.000 description 2
- VWBAHTCOVBWTMX-UHFFFAOYSA-N 1-(5-tert-butyl-1h-pyrazol-3-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 VWBAHTCOVBWTMX-UHFFFAOYSA-N 0.000 description 2
- JDKYGCYHGTVUOU-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(3-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2C=CN=CC=2)=C1 JDKYGCYHGTVUOU-UHFFFAOYSA-N 0.000 description 2
- HFVZEWHYOCNZGL-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 HFVZEWHYOCNZGL-UHFFFAOYSA-N 0.000 description 2
- UYYMFPJGZUWZKS-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound S1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(SC=3C=CN=CC=3)=CC=2)=C1 UYYMFPJGZUWZKS-UHFFFAOYSA-N 0.000 description 2
- WKAIPJMBCLQCSX-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(3-methylphenoxy)phenyl]urea Chemical compound CC1=CC=CC(OC=2C=CC(NC(=O)NC=3C=C(SC=3)C(C)(C)C)=CC=2)=C1 WKAIPJMBCLQCSX-UHFFFAOYSA-N 0.000 description 2
- KUMIMKXLYUJKTQ-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(4-hydroxyphenoxy)phenyl]urea Chemical compound S1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CC(O)=CC=3)=CC=2)=C1 KUMIMKXLYUJKTQ-UHFFFAOYSA-N 0.000 description 2
- TXGSEPBWHRRHQE-UHFFFAOYSA-N 1-(5-tert-butylthiophen-3-yl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CSC(C(C)(C)C)=C1 TXGSEPBWHRRHQE-UHFFFAOYSA-N 0.000 description 2
- RAAIQRXSFVOCHG-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(3-tert-butyl-1,2-oxazol-5-yl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2SC3=CC=CC=C3N=2)=C1 RAAIQRXSFVOCHG-UHFFFAOYSA-N 0.000 description 2
- XHWVFNIWFYIPIZ-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(OC=3SC4=CC=CC=C4N=3)C=CC=2)=N1 XHWVFNIWFYIPIZ-UHFFFAOYSA-N 0.000 description 2
- RHSMGLCDPGODHW-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yloxy)phenyl]-3-(5-tert-butyl-2-methylpyrazol-3-yl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(OC=2SC3=CC=CC=C3N=2)=C1 RHSMGLCDPGODHW-UHFFFAOYSA-N 0.000 description 2
- RMNIXRMFHYBQQB-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 RMNIXRMFHYBQQB-UHFFFAOYSA-N 0.000 description 2
- OLAYKASHGVRXIZ-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 OLAYKASHGVRXIZ-UHFFFAOYSA-N 0.000 description 2
- JYGHRSVBJYNRTB-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 JYGHRSVBJYNRTB-UHFFFAOYSA-N 0.000 description 2
- JBQPNUNIDPHVFQ-UHFFFAOYSA-N 1-[3-(2-methylbutan-2-yl)-1,2-oxazol-5-yl]-3-[4-(4-methylphenoxy)phenyl]urea Chemical compound O1N=C(C(C)(C)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=C(C)C=C1 JBQPNUNIDPHVFQ-UHFFFAOYSA-N 0.000 description 2
- GCBVDYBTNTVVOV-UHFFFAOYSA-N 1-[3-(3-methylpentan-3-yl)-1,2-oxazol-5-yl]-3-(3-pyridin-4-ylsulfanylphenyl)urea Chemical compound O1N=C(C(C)(CC)CC)C=C1NC(=O)NC1=CC=CC(SC=2C=CN=CC=2)=C1 GCBVDYBTNTVVOV-UHFFFAOYSA-N 0.000 description 2
- HCQRNJBKBZFSAB-UHFFFAOYSA-N 1-[3-(3-methylpentan-3-yl)-1,2-oxazol-5-yl]-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound O1N=C(C(C)(CC)CC)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 HCQRNJBKBZFSAB-UHFFFAOYSA-N 0.000 description 2
- VZQCQRSYTUIZKV-UHFFFAOYSA-N 1-[4-(4-acetylphenoxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound C1=CC(C(=O)C)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 VZQCQRSYTUIZKV-UHFFFAOYSA-N 0.000 description 2
- JTOAETRLMJYYMY-UHFFFAOYSA-N 1-[4-(7ah-1,3-benzodioxol-3a-yloxy)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC34C(OCO3)C=CC=C4)=CC=2)=N1 JTOAETRLMJYYMY-UHFFFAOYSA-N 0.000 description 2
- WGTGBBYSTFTSFN-UHFFFAOYSA-N 3-[3-[(5-tert-butyl-1h-pyrazol-3-yl)carbamoylamino]phenoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(OC=2C=C(NC(=O)NC=3NN=C(C=3)C(C)(C)C)C=CC=2)=C1 WGTGBBYSTFTSFN-UHFFFAOYSA-N 0.000 description 2
- YRVHIOAIPPJICO-UHFFFAOYSA-N 3-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]sulfanyl-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(SC=2C=CC(NC(=O)NC3=NOC(=C3)C(C)(C)C)=CC=2)=C1 YRVHIOAIPPJICO-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99634397A | 1997-12-22 | 1997-12-22 | |
| US08/996,343 | 1997-12-22 | ||
| PCT/US1998/026078 WO1999032106A1 (en) | 1997-12-22 | 1998-12-22 | Inhibition of raf kinase using substituted heterocyclic ureas |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009237917A Division JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237895A Division JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001526220A JP2001526220A (ja) | 2001-12-18 |
| JP2001526220A5 true JP2001526220A5 (enExample) | 2006-01-05 |
| JP4437270B2 JP4437270B2 (ja) | 2010-03-24 |
Family
ID=25542800
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525097A Expired - Fee Related JP4437270B2 (ja) | 1997-12-22 | 1998-12-22 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237895A Pending JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237917A Pending JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009237895A Pending JP2010065041A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| JP2009237917A Pending JP2010065042A (ja) | 1997-12-22 | 2009-10-15 | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1047418B1 (enExample) |
| JP (3) | JP4437270B2 (enExample) |
| KR (1) | KR100571588B1 (enExample) |
| CN (2) | CN100360507C (enExample) |
| AT (1) | ATE300299T1 (enExample) |
| AU (1) | AU2198999A (enExample) |
| BG (1) | BG64984B1 (enExample) |
| BR (1) | BR9814374B1 (enExample) |
| CA (1) | CA2315717C (enExample) |
| CU (1) | CU23126A3 (enExample) |
| CZ (1) | CZ299156B6 (enExample) |
| DE (2) | DE1047418T1 (enExample) |
| DK (1) | DK1047418T3 (enExample) |
| ES (1) | ES2153340T3 (enExample) |
| GR (1) | GR20010300007T1 (enExample) |
| HU (1) | HUP0101704A3 (enExample) |
| ID (1) | ID26620A (enExample) |
| IL (2) | IL136767A0 (enExample) |
| NO (1) | NO326150B1 (enExample) |
| NZ (1) | NZ505844A (enExample) |
| PL (1) | PL205321B1 (enExample) |
| RU (1) | RU2232015C2 (enExample) |
| SK (1) | SK286213B6 (enExample) |
| TR (1) | TR200002618T2 (enExample) |
| UA (1) | UA71904C2 (enExample) |
| WO (1) | WO1999032106A1 (enExample) |
Families Citing this family (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69826695T2 (de) * | 1997-05-23 | 2006-02-02 | Bayer Pharmaceuticals Corp., West Haven | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
| US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| EP1449834A3 (en) * | 1997-12-22 | 2004-12-22 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| EP1157026A1 (en) | 1999-02-22 | 2001-11-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
| JP2002538151A (ja) | 1999-03-02 | 2002-11-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンの可逆的インヒビターとして有用な化合物 |
| PL350357A1 (en) | 1999-03-12 | 2002-12-02 | Boehringer Ingelheim Pharma | Heterocyclic urea and related compounds useful as anti−inflammatory agents |
| DE60023853T2 (de) * | 1999-03-12 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| JP4955171B2 (ja) | 1999-11-16 | 2012-06-20 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての尿素誘導体 |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| SK2002003A3 (en) * | 2000-08-31 | 2004-04-06 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2443950C (en) * | 2001-04-20 | 2011-10-18 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| AU2002255284B2 (en) | 2001-04-27 | 2007-10-04 | Kyowa Kirin Co., Ltd. | Quinoline derivative having azolyl group and quinazoline derivative |
| CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| JP2004531571A (ja) | 2001-05-25 | 2004-10-14 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物 |
| AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| ATE345130T1 (de) * | 2001-12-03 | 2006-12-15 | Bayer Pharmaceuticals Corp | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen |
| BRPI0214840B8 (pt) | 2001-12-21 | 2021-05-25 | The Wellcome Trust | métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa |
| PT1580188E (pt) | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aril-ureias como inibidores de cinases |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| JP4629978B2 (ja) | 2002-02-25 | 2011-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物 |
| AR038703A1 (es) | 2002-02-28 | 2005-01-26 | Novartis Ag | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| WO2004035572A1 (ja) * | 2002-10-21 | 2004-04-29 | Kirin Beer Kabushiki Kaisha | Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形 |
| EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| MXPA05009104A (es) | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos. |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| ATE489379T1 (de) * | 2003-02-28 | 2010-12-15 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| MXPA05010020A (es) * | 2003-03-24 | 2005-11-17 | Merck Patent Gmbh | Derivados de oxamida. |
| EP1611128A2 (en) * | 2003-03-28 | 2006-01-04 | Pharmacia & Upjohn Company LLC | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| JP4939220B2 (ja) | 2003-05-15 | 2012-05-23 | アークル インコーポレイテッド | ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体 |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| JP4750701B2 (ja) * | 2003-07-07 | 2011-08-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | マロンアミド誘導体 |
| RS52625B (sr) | 2003-07-23 | 2013-06-28 | Bayer Healthcare Llc | Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| CA2545711A1 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
| WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| WO2005100338A1 (en) * | 2004-04-13 | 2005-10-27 | Astex Therapeutics Limited | 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
| ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
| US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| MXPA06013118A (es) * | 2004-05-12 | 2007-02-28 | Schering Corp | Antagonistas de cxcr1 y cxcr2 de quimocina. |
| MXPA06014495A (es) | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
| US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| EP1778686B9 (en) | 2004-08-12 | 2009-07-08 | Pfizer Limited | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| EP1645556A1 (en) * | 2004-10-07 | 2006-04-12 | Boehringer Ingelheim International GmbH | Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents |
| WO2006044869A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| WO2006076592A1 (en) | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| US20060199846A1 (en) * | 2005-01-14 | 2006-09-07 | Mitchell Scott A | Certain substituted ureas as modulators of kinase activity |
| KR101335932B1 (ko) | 2005-03-07 | 2013-12-04 | 바이엘 헬스케어 엘엘씨 | 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물 |
| DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| WO2007024294A2 (en) | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| JP5072595B2 (ja) | 2005-08-05 | 2012-11-14 | 中外製薬株式会社 | マルチキナーゼ阻害剤 |
| DE102005037499A1 (de) | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| WO2007059202A2 (en) * | 2005-11-15 | 2007-05-24 | Bayer Healthcare Ag | Pyrazolyl urea derivatives useful in the treatment of cancer |
| JP2009518298A (ja) * | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| ES2480440T3 (es) * | 2005-12-21 | 2014-07-28 | Bayer Intellectual Property Gmbh | Derivados sustituidos de pirimidina útiles en el tratamiento del cáncer y de otros trastornos |
| WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| KR101549364B1 (ko) | 2006-03-17 | 2015-09-01 | 암비트 바이오사이언시즈 코포레이션 | 질환 치료용 이미다졸로티아졸 화합물 |
| PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| US20080045589A1 (en) | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| US20100150863A1 (en) | 2006-12-20 | 2010-06-17 | Bayer Pharmaceuticals Corporation | Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| AU2008242720A1 (en) * | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
| US8883783B2 (en) | 2007-09-19 | 2014-11-11 | Ambit Biosciences Corporation | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| MX2010009410A (es) | 2008-02-29 | 2010-11-30 | Array Biopharma Inc | Compuestos del inhibidor de raf y métodos de uso de los mismos. |
| CL2009000448A1 (es) | 2008-02-29 | 2009-11-27 | Genentech Inc | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010067130A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| EA031116B1 (ru) | 2009-04-03 | 2018-11-30 | Ф. Хоффманн-Ля Рош Аг | КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| JP2012529517A (ja) | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ベンジル置換トリアジン誘導体類及びそれらの治療応用 |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| UA105813C2 (uk) | 2009-11-06 | 2014-06-25 | Плексікон, Інк. | Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти) |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US20130225581A1 (en) | 2010-07-16 | 2013-08-29 | Kyowa Hakko Kirin Co., Ltd | Nitrogen-containing aromatic heterocyclic derivative |
| WO2012008564A1 (ja) * | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| US20130183268A1 (en) | 2010-07-19 | 2013-07-18 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| PL2672967T3 (pl) * | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania ku temu |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EP2875014B1 (en) * | 2012-07-17 | 2017-11-29 | Washington University | Anti-mucus drugs and uses therefor |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| WO2015066490A1 (en) | 2013-10-31 | 2015-05-07 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| US10023567B2 (en) | 2014-07-18 | 2018-07-17 | Ohio University | Imidazole and thiazole compositions for modifying biological signaling |
| DK3180335T3 (da) | 2014-08-11 | 2021-08-09 | Angion Biomedica Corp | Cytokrom-p450-inhibitorer og anvendelser deraf |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| RS58813B1 (sr) | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
| MX381233B (es) * | 2014-09-10 | 2025-03-12 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret). |
| US9638690B2 (en) | 2014-11-07 | 2017-05-02 | The University Of British Columbia | Compounds and compositions for use as alkylating agent sensors and methods of use thereof |
| EP3240778A4 (en) | 2014-12-31 | 2018-07-11 | Angion Biomedica Corp. | Methods and agents for treating disease |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US10519113B2 (en) * | 2016-08-17 | 2019-12-31 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds, compositions, and methods of treating cancer |
| CN106866571B (zh) * | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| KR20210020866A (ko) | 2018-06-12 | 2021-02-24 | 브이티브이 테라퓨틱스 엘엘씨 | 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도 |
| CN110903245B (zh) * | 2018-09-17 | 2022-11-22 | 南京药石科技股份有限公司 | 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法 |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| WO2021013712A1 (en) * | 2019-07-19 | 2021-01-28 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ，エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| SI4084778T1 (sl) | 2019-12-30 | 2024-01-31 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitorja amorfne kinaze in načini njihove uporabe |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN113966331B (zh) * | 2020-03-11 | 2024-04-12 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
| TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Ｃｄｋ２抑制劑及其製備方法 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2024126777A1 (en) * | 2022-12-16 | 2024-06-20 | Astrazeneca Ab | Heteroaromatic compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
| JPS5031039A (enExample) * | 1973-07-27 | 1975-03-27 | ||
| US3990879A (en) * | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
| US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
| US4042372A (en) * | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
| JPS5386033A (en) * | 1977-10-20 | 1978-07-29 | Shionogi & Co Ltd | Herbicides |
| DE3612830A1 (de) * | 1986-04-16 | 1987-10-22 | Basf Ag | Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen |
| FR2639636B1 (fr) * | 1988-11-30 | 1994-03-04 | Novapharme | Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant |
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| JPH06500551A (ja) * | 1990-09-13 | 1994-01-20 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | ５ｈｔ受容体アンタゴニストとしてのインドールウレア |
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| US5185358A (en) * | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
| US5508288A (en) * | 1992-03-12 | 1996-04-16 | Smithkline Beecham, P.L.C. | Indole derivatives as 5HT1C antagonists |
| WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
| EP0784612A1 (en) * | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| TR199802136T2 (xx) * | 1996-04-23 | 2001-06-21 | Vertex Pharmaceuticals Incorporated | �MPDH enzimi inhibit�rleri olarak �re t�revleri. |
| GB9623833D0 (en) * | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
| JP2002500650A (ja) * | 1997-05-23 | 2002-01-08 | バイエル、コーポレイション | Ｒａｆキナーゼ阻害剤 |
| GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| DE69834842T2 (de) * | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
| ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
-
1998
- 1998-12-22 EP EP98965981A patent/EP1047418B1/en not_active Expired - Lifetime
- 1998-12-22 WO PCT/US1998/026078 patent/WO1999032106A1/en not_active Ceased
- 1998-12-22 CN CNB2004100286556A patent/CN100360507C/zh not_active Expired - Fee Related
- 1998-12-22 CZ CZ20002350A patent/CZ299156B6/cs not_active IP Right Cessation
- 1998-12-22 AT AT98965981T patent/ATE300299T1/de active
- 1998-12-22 CN CNB988136236A patent/CN1149085C/zh not_active Expired - Fee Related
- 1998-12-22 ES ES98965981T patent/ES2153340T3/es not_active Expired - Lifetime
- 1998-12-22 DK DK98965981T patent/DK1047418T3/da active
- 1998-12-22 IL IL13676798A patent/IL136767A0/xx active IP Right Grant
- 1998-12-22 PL PL343083A patent/PL205321B1/pl not_active IP Right Cessation
- 1998-12-22 JP JP2000525097A patent/JP4437270B2/ja not_active Expired - Fee Related
- 1998-12-22 DE DE1047418T patent/DE1047418T1/de active Pending
- 1998-12-22 RU RU2000120184/15A patent/RU2232015C2/ru not_active IP Right Cessation
- 1998-12-22 SK SK963-2000A patent/SK286213B6/sk not_active IP Right Cessation
- 1998-12-22 TR TR2000/02618T patent/TR200002618T2/xx unknown
- 1998-12-22 UA UA2000074352A patent/UA71904C2/uk unknown
- 1998-12-22 DE DE69831013T patent/DE69831013T2/de not_active Expired - Lifetime
- 1998-12-22 KR KR1020007006929A patent/KR100571588B1/ko not_active Expired - Fee Related
- 1998-12-22 BR BRPI9814374-3B1A patent/BR9814374B1/pt not_active IP Right Cessation
- 1998-12-22 AU AU21989/99A patent/AU2198999A/en not_active Abandoned
- 1998-12-22 NZ NZ505844A patent/NZ505844A/en not_active IP Right Cessation
- 1998-12-22 ID IDW20001429A patent/ID26620A/id unknown
- 1998-12-22 CA CA2315717A patent/CA2315717C/en not_active Expired - Fee Related
- 1998-12-22 HU HU0101704A patent/HUP0101704A3/hu unknown
-
2000
- 2000-06-14 IL IL136767A patent/IL136767A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003232A patent/NO326150B1/no not_active IP Right Cessation
- 2000-06-22 CU CU154A patent/CU23126A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104597A patent/BG64984B1/bg unknown
-
2001
- 2001-02-28 GR GR20010300007T patent/GR20010300007T1/el unknown
-
2009
- 2009-10-15 JP JP2009237895A patent/JP2010065041A/ja active Pending
- 2009-10-15 JP JP2009237917A patent/JP2010065042A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001526220A5 (enExample) | ||
| CA2315717A1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| RU2000120184A (ru) | Способ подавления роста опухолевых клеток, опосредованного киназой raf, гетероциклические производные мочевины (варианты), фармацевтическая композиция (варианты) | |
| KR930005992A (ko) | 루코트리엔 생합성 억제제 | |
| JP2004504301A5 (enExample) | ||
| CA2418868A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| RU2003105805A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1 | |
| JP2002534468A5 (enExample) | ||
| JP2001526269A5 (enExample) | ||
| CA2404125A1 (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
| JP2007502264A5 (enExample) | ||
| US6313153B1 (en) | Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives | |
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2005509024A5 (enExample) | ||
| KR20060066711A (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| JPWO1999046232A1 (ja) | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 | |
| JP2007504284A5 (enExample) | ||
| RU2007124187A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| CA2536954A1 (en) | C-kit modulators and methods of use | |
| SI9210092B (en) | N-phenylcarbamate compound, procedure for its preparation and biocidal composition for pest control | |
| JP2007501831A5 (enExample) | ||
| JPH0386864A (ja) | 強心剤 | |
| JPWO2022032068A5 (enExample) | ||
| JP2006525990A5 (enExample) | ||
| JP2005519885A5 (enExample) |